US Patent

US12329851 — Long acting injectable formulation comprising risperidone and biodegradable polymers

Method of Use · Assigned to MedinCell SA · Expires 2042-03-17 · 16y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating psychiatric diseases and disorders by administering a specific injectable formulation of risperidone at a frequency of no more than once every 28 days.

USPTO Abstract

The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof at a frequency of no more than once every 28 days an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal
`U-4214`	—	Risperdal

Patent Metadata

Patent number: US12329851
Jurisdiction: US
Classification: Method of Use
Expires: 2042-03-17
Drug substance claim: No
Drug product claim: No
Assignee: MedinCell SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.